Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CRM
IHD
Cosentyx® - Anti IL-17
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milesstone(s)
Publication
75 Investor Relations | Q2 2021 Results
NCT03589885 MATURE (CAIN457A2325)
Psoriasis
Phase 3
NCT03668613 (CAIN457A2311)
Psoriasis
Phase 3
122
84
PASI 75 response and IGA mod 2011 0 or 1 response after 12 weeks of treatment
Secukinumab 2 mL (300 mg) auto-injector
Secukinumab 2 x 1 mL (150 mg each) prefilled syringe
Placebo 2 mL auto-injector
Placebo 2 x 1 mL prefilled syringe
Subjects with moderate to severe plaque psoriasis
Final: Q4-2020
Sigurgeirsson et al, Presentation at AAD VMX 2021 (16-week)
IFPA 2021 (planned)
EADV 2021 (planned)
52-week publication H2-2021
Psoriasis Area and Severity Index (PASI) 75 response and Investigators' Global
Assessment (IGA) 0 or 1 response at week 12
Secukinumab low dose
Secukinumab high dose
Pediatric patients of age 6 to <18 years, with moderate to severe plaque psoriasis
2023
24-week paper publication in Q3 2021 (estimate).
Magnolo et al. Presentation at AAD VMX 2021.
Magnolo et al. Presentation at ESPD 2021.
SPD (Q3 2021 - planned)
EADV (Q3 2021 - planned) - pooled A2310/A2311
PG2C (Q4 2021 - planned) - pooled A2310/A2311
1 NOVARTIS | Reimagining MedicineView entire presentation